Phase 1/2 study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody bgb-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors.

被引：2
|
作者：
Desai, Jayesh
Voskoboynik, Mark
Markman, Ben
Hou, Jeannie
Zeng, Dewan
Meniawy, Tarek
机构：
[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[2] Royal Melbourne Hosp, Melbourne, Vic, Australia
[3] Nucleus Network, Melbourne, Vic, Australia
[4] Monash Hlth, Melbourne, Vic, Australia
[5] Monash Univ, Melbourne, Vic, Australia
[6] BeiGene USA Inc, Emeryville, CA USA
[7] Univ Western Australia, Sir Charles Gairdner Hosp, Nedlands, WA, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS3113
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3113
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase I/II study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody BGB-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors
    Desai, J.
    Voskoboynik, M.
    Markman, B.
    Hou, J.
    Zeng, D.
    Meniawy, T.
    ANNALS OF ONCOLOGY, 2018, 29 : 146 - 146
  • [2] BGB-A333, an anti-PD-L1 monoclonal antibody, in combination with tislelizumab in patients with urothelial carcinoma
    Martin Liberal, J.
    Fong, P. C.
    Moreno, V.
    Frentzas, S.
    Desai, J.
    Meniawy, T.
    Markman, B.
    Voskoboynik, M.
    Budha, N.
    Wu, J.
    Shen, W.
    Singh, M.
    Calvo, E.
    ANNALS OF ONCOLOGY, 2020, 31 : S468 - S469
  • [3] A phase 1 study of serplulimab, a novel humanized monoclonal anti-PD-1 antibody, in patients with advanced solid tumors.
    Ho, Ching-Liang
    Chao, Tsu-Yi
    Chang, Chia Lun
    Lin, Hsuan-Yu
    Yang, Futang
    Wang, Qingyu
    Zhu, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] A Phase 1B Study of the Anti-PD-1 Monoclonal Antibody, Tislelizumab, in Combination with the Parp Inhibitor, Pamiparib, in Advanced Solid Tumors
    Friedlander, M.
    Meniawy, T.
    Markman, B.
    Mileshkin, L. R.
    Harnett, P.
    Millward, M.
    Lundy, J.
    Freimund, A. E.
    Norris, C.
    Wu, J.
    Paton, V.
    Wang, L.
    Gao, B.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 58 - 59
  • [5] A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours
    Jayesh Desai
    Peter Fong
    Victor Moreno
    Sophia Frentzas
    Tarek Meniawy
    Ben Markman
    Mark Voskoboynik
    Tahmina Rahman
    Nageshwar Budha
    John Wu
    Jin Marlow
    Silu Yang
    Emiliano Calvo
    Juan Martin-Liberal
    British Journal of Cancer, 2023, 128 : 1418 - 1428
  • [6] A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours
    Desai, Jayesh
    Fong, Peter
    Moreno, Victor
    Frentzas, Sophia
    Meniawy, Tarek
    Markman, Ben
    Voskoboynik, Mark
    Rahman, Tahmina
    Budha, Nageshwar
    Wu, John
    Marlow, Jin
    Yang, Silu
    Calvo, Emiliano
    Martin-Liberal, Juan
    BRITISH JOURNAL OF CANCER, 2023, 128 (08) : 1418 - 1428
  • [7] A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors
    Desai, Jayesh
    Davar, Diwakar
    Deva, Sanjeev
    Gao, Bo
    Liu, Tianshu
    Matos, Marco
    Meniawy, Tarek
    O'Byrne, Kenneth John
    Sun, Meili
    Voskoboynik, Mark
    Yang, Kunyu
    Yu, Xinmin
    Chen, Xin
    Dong, Yan
    Giovinazzo, Hugh
    Leaw, Shiangjiin
    Patel, Deepa
    Rahman, Tahmina
    Wu, Yanjie
    Day, Daphne
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] Bgb-A425, an investigational anti-TIM-3 monoclonal antibody, in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: A phase I/II trial in progress.
    Desai, Jayesh
    Meniawy, Tarek
    Beagle, Brandon
    Li, ZheZhen
    Mu, Song
    Wu, John
    Denlinger, Crystal S.
    Messersmith, Wells A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Dostarlimab Anti-PD-1 monoclonal antibody Treatment of advanced solid tumors
    Haddley, K.
    DRUGS OF THE FUTURE, 2019, 44 (07) : 527 - 534
  • [10] A phase 1 study of the safety, tolerability, and pharmacokinetics (PK) of MGA012 (anti-PD-1 antibody) in patients with advanced solid tumors
    Lakhani, Nehal
    Mehnert, Janice M.
    Rasco, Drew
    Gordon, Michael
    Lohr, Joanna
    Pencheva, Pepi
    Sharma, Sharad
    Li, Hua
    LaMotte-Mohs, Ross
    Moore, Paul
    Sun, Jichao
    Sumrow, Bradley
    Wigginton, Jon
    Powderly, John
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
12345